ZIMVIE INC Stock Price, News & Analysis

ZimVie (NASDAQ: ZIMV) reported its Q4 and FY2024 financial results, marking a transformational year as a pure-play dental company. Full-year 2024 third-party net sales reached $449.7 million, down 1.6% from 2023, with a net loss of $(33.8) million. The company achieved an Adjusted EBITDA of $60.0 million with a 13.3% margin.

In Q4 2024, third-party net sales were $111.5 million, decreasing 1.4% year-over-year, with a net loss of $(9.7) million. However, this represented a $12.5 million improvement from Q4 2023's loss. The quarter's Adjusted EBITDA reached $18.4 million, with a 16.5% margin, showing a 420 basis points increase.

Notable achievements include reducing net debt by over $290 million, streamlining operations through corporate cost reduction, and implementing manufacturing efficiency initiatives. Despite softer end markets, the company improved its Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023.

ZimVie Inc (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced it will release its fourth quarter and full-year 2024 financial results after market close on Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested participants are advised to register online more than 15 minutes before the call begins. A replay of the webcast will be made available on the company's investor relations website.

ZimVie Inc. (NASDAQ: ZIMV) announced the publication of a scientific study in the Journal of Biomedical Materials Research demonstrating the advantages of their dental implant surface technology. The study compared ZimVie's T3® PRO and TSX® Implants' dual acid-etched coronal surface technology with other leading implant brands.

The research identified a critical threshold roughness for dental implants, below which bacterial adhesion remains similar to smooth machined surfaces. ZimVie's implants' coronal surfaces, DAE and Osseotite®, are engineered around this threshold, showing bacterial adhesion levels comparable to machined surfaces while maintaining crestal bone levels similar to rougher surfaces.

The findings suggest that ZimVie's implants may help reduce the risk of peri-implant infections compared to other commercial implants, addressing the growing concern of peri-implant mucositis and peri-implantitis in dental implantology.

ZimVie Inc. (ZIMV) reported Q3 2024 financial results with third-party net sales of $103.2 million, showing a 2.0% decrease from Q3 2023. The company posted a net loss of $(3.0) million, improving from a $(10.2) million loss in the previous year. Adjusted EBITDA reached $13.1 million with a 12.7% margin, up 110 basis points year-over-year. The company reported GAAP diluted EPS of $(0.11) and adjusted diluted EPS of $0.12. ZimVie updated its full-year 2024 guidance, projecting net sales between $450M to $455M and adjusted EBITDA between $60M to $62M.

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, November 12, 2024, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.

Interested parties can access both the live webcast and an archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call to discuss the results, beginning at 4:30 p.m. Eastern Time on the same day.

Interested parties can register for the conference call online. It is recommended to register more than 15 minutes before the call starts. For those unable to attend the live call, a replay of the webcast will be made available on the company's investor relations website at investor.zimvie.com.

ZimVie Inc. (ZIMV) reported Q2 2024 financial results for its continuing operations in the dental market. Key highlights include:

- Third party net sales of $116.8 million, down 1.5% year-over-year
- Net loss of $(9.6) million, with a net loss margin of 8.2%
- Adjusted EBITDA of $16.1 million, with a 13.8% margin
- Reduced debt to $235.1 million
- Cash balance of $78.6 million

The company reaffirmed its full-year 2024 guidance, projecting net sales of $450-$460 million, adjusted EBITDA of $60-$65 million, and adjusted EPS of $0.55-$0.70. CEO Vafa Jamali highlighted progress in customer engagement, product innovation, and operational improvements.

ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:

1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.

2. New restorative design workflows to meet evolving clinic and dental laboratory needs.

3. Amplified CAD workflows for creating attractive implant dentistry designs.

4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.

5. Cloud-based design libraries for improved accessibility.

The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.

ZimVie Inc. (Nasdaq: ZIMV) has announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio, following FDA 510(k) clearance. This launch expands ZimVie's end-to-end prosthetic offerings in the dental market. The GenTek portfolio, first introduced in Europe in 2019, includes Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products for digitally driven CAD/CAM restorations.

Designed to mate with ZimVie implant systems, GenTek components ensure a perfect fit and tight seal for long-term aesthetic and functional restorations. The company anticipates strong demand in the U.S. market, following the product's success in Europe.